Tofersen + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Conditions
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Trial Timeline
May 17, 2021 → Aug 7, 2027
NCT ID
NCT04856982About Tofersen + Placebo
Tofersen + Placebo is a phase 3 stage product being developed by Biogen for Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT04856982. Target conditions include Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation.
What happened to similar drugs?
2 of 17 similar drugs in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation were approved
Approved (2) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04856982 | Phase 3 | Active |
| NCT02623699 | Phase 3 | Completed |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 17 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 35 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 18 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 38 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 38 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 40 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 35 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 36 |
| TCH346 | Novartis | Phase 2 | 35 |
| VHB937 | Novartis | Phase 2 | 39 |
| TCH346 | Novartis | Phase 2 | 35 |
| TCH346 | Novartis | Phase 2 | 35 |
| BLZ945 | Novartis | Phase 2 | 27 |
| TRO19622 | Roche | Phase 2/3 | 38 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 40 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 28 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 35 |